A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

This systematic review and network meta-analysis of 601 eligible trials found that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1 receptor agonists were ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

The study offers promising news for people with type 2 diabetes. By using SGLT2 inhibitors, they may be able to lower their ...

Tatsuya Yoshida, Mikito Takefuji, and Toyoaki Murohara in the Department of Cardiology, Nagoya University Graduate School of Medicine, identified an enzyme, alpha-kinase 2 (ALPK2) that is specifically ...

The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6%.